ProCE Banner Activity

EPCORE NHL-1: Update From First-in-Human Phase I/II Trial of Epcoritamab, an Anti-CD3/Anti-CD20 Bispecific Antibody, in R/R B-Cell NHL

Slideset Download
Conference Coverage
Based on longer follow-up data, epcoritamab continues to show a manageable safety profile, with low-grade CRS, along with high response rates at doses ranging from 0.75-60 mg across disease histologies.

Released: June 07, 2021

Expiration: June 06, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme